July 1984

Review of the Overall Experience of Captopril in Hypertension

Author Affiliations

From the Alton Ochsner Medical Foundation, New Orleans (Dr Frohlich); the Hematology-Oncology Section, University of Pennsylvania Hospital, Philadelphia (Dr Cooper); and the Department of Medicine, Rush-Presbyterian—St Luke's Medical Center, Chicago (Dr Lewis).

Arch Intern Med. 1984;144(7):1441-1444. doi:10.1001/archinte.1984.00350190137023

• The pharmacologic profile of the angiotensin—converting enzyme inhibitor, captopril, is described. After reviewing the total clinical experience of captopril from the world literature and manufacturer's files, a small subgroup of clinically complex patients at particular risk of side effects and in whom the drug must be used with caution is characterized. Evidence is available that demonstrates that lower doses (150 mg/day or less, with modest doses of diuretic agents) are effective in both short- and long-term therapy, while the incidence of side effects is substantially reduced. With this background information, the benefit-risk ratio is substantially improved and the use of captopril as a primary agent in the management of hypertension may be considered.

(Arch Intern Med 1984;144:1441-1444)